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Sllmmary 
Interleukin 7 (II:7) is a 25-kD cytokine that was initially described as a pre-B cell growth factor. 
This cytokine has also been shown to have T cell proliferative and differentiation effects.  In this 
report, we demonstrate that antitumor cytotoxic T lymphocytes (CTL) generated by secondary 
in vitro sensitization of draining lymph node cells in Ib7 are effective in treating 3-day syngeneic 
methylcholanthrene (MCA) sarcoma pulmonary metastases in mice. In vivo titrations comparing 
Ib7 to Ib2 antitumor CTL show that they have equivalent potency in adoptive immunotherapy. 
II+-7 antitumor CTL generated against MCA sarcomas of weak immunogeneity are also tumor 
specific in their in vivo efficacy. This study represents the first successful use of a cytokine other 
than  IL-2 for the generation  of cells with  in vivo efficacy in cellular  adoptive transfer. 
G 
eneration of antitumor cells with activity in vitro and 
therapeutic  efficacy  in  vivo has  been described with 
lymphokine-activated killer (LAK) t cells, tumor-infiltrating 
lymphocytes (TIL), and secondary in vitro sensitized CTL 
(1). In all of these methods of effector cell generation for adop- 
tive immunotherapy,  II+-2 has played a necessary role in lym- 
phocyte culture and as a supportive agent for the transferred 
cells in vivo. While I1..2 is of prime importance in the gener- 
ation of antitumor cytotoxic T  cells,  further search has un- 
covered other cytokines with T cell-activating and -prolifer- 
ative capacity,  including  I1+-4 (2,  3) and I1:6 (4,  5). 
Recently, after the identification of a soluble molecule with 
pre-B cell growth factor activity, IL-7 was cloned (6-8) and 
shown to promote the proliferation  of murine  thymocytes 
(9-11), mature T  cells (12-14), as well as the generation of 
lytic CTL with alloreactivity from thymocytes (15). We have 
recently shown that II.-7 was capable of generating antitumor 
CTL with similar cytolytic activity and enhanced specificity 
in StCr release when compared to those generated with IL-2 
(Jicha, D. L., S. Schwarz, J. J. MulE,  and S. A. Rosenberg, 
manuscript submitted for publication). In this report, we now 
demonstrate the in vivo efficacy and specificity of IL-7-gen- 
erated antitumor CTL in mice bearing tumor metastases and 
compare this efficacy to that  of antitumor  CTL generated 
in  Ib2. 
1Abbreviations used in  this paper: DLN,  draining lymph node; LAK, 
lymphokine-activated killer; MCA, methylcholanthrene; TIL, tumor- 
infiltrating lymphocytes. 
Materials and Methods 
M~:~  Female  C57BL/6n (denoted B6) mice were obtained from 
the Animal Production Colonies of the National Cancer Institute, 
Frederick facility (Frederick, MD), and from the Charles River 
Breeding Laboratories, Inc. (Wilmington,  MA). 
Tumors.  The methylcholanthrene (MCA)-induced 203 and 205 
tumors are weakly immunogenic fibrosarcomas of B6 origin main- 
tained in vivo by subcutaneous passage in syngeneic mice. All tumors 
were used fresh and were prepared as described previously (16). 
Cytokines.  Purified human rib7 was a gift of Sterling Drug, 
Inc. (Malvern, PA). Two lots of IL-7 were used, one with a specific 
activity of 4.7  x  107 U/mg of protein and another with a specific 
activity of 5.6  x  107 U/mg, as determined by bioassay using the 
Ib7-dependent IxN/2b pre-B cell line (6). Human rib2 was a gift 
of Cetus Corp. (Emeryvilh, CA). Lyophilized  Ib2 was reconstituted 
in sterile water to 106 U/ml, as confirmed in a bioassay using Ib 
2-dependent  CTLL (17). 
Antitumor CTL Cultures.  Popliteal  draining lymph nodes (DLN) 
were removed in sterile conditions  7 d after footpad inoculation 
of B6 mice with 106 MCA 203 or 205 tumors in 0.05 ml. Single- 
cell suspensions were prepared by crushing the DLN with the blunt 
end of a syringe plunger and subsequent filtration through nylon 
mesh. Cultures  were carried out in 8-ml, six-well plates (Costar, 
Cambridge,  MA) with 4  x  10  s DLN/ml. DLN were cocultured 
with 2  x  10S/ml MCA 203 or 205 (as appropriate per footpad 
inoculation)  previously irradiated with 2,000 rad. Cultures  were 
generated in Ib7 (100 ng/ml),  IL-2 (20 U/m1), Ib7 (100 ng/ml) 
plus Ib2 (20 U/ml), or no cytokine as noted.  In all cases, cells 
were cultured for 11 d before use in adoptive transfer experiments. 
AdoFtive ImmunotheraFy Models.  B6 mice were injected intrave- 
nously, via lateral tail vein, with 5  x  10  s MCA 203 or 205 tumor 
ceUs in 1 ml of HBSS, to induce pulmonary metastases. On day 
3 after delivery of tumor cells, therapeutic cells were injected intra- 
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14-17 after initial  tumor delivery, pulmonary  metastases were 
enumerated as described previously (17). 
StatisticalAnalysis.  Significant  differences  in the number of  pul- 
monary metastases among groups were analyzed  by the Wilcoxon 
rank sum test. Two-sided  jv values are presented in all cases. 
Results  and  Discussion 
To test the in vivo efficacy  of I1:7-generated antitumor CTL 
obtained from DLN, we used a 3-d pulmonary metastatic 
model with the syngeneic MCA 203 sarcoma.  Cell cultures 
were established in complete media without added cytokine 
in parallel with I1:7,  I1:2,  and I1:7 plus I1:2-supplemented 
cultures. Antitumor CTL were delivered intravenously once 
followed by I1:2 10,000 U  given twice daily for 5 d begin- 
ning immediately after adoptive cell transfer.  As shown in 
Table  1,  I1:7  and  I1:2  cultures  were  equally effective  in 
eradicating metastatic disease at titrated cell doses. I1:7 plus 
I1:2 cultures were equivalent to or slightly  poorer in eradicating 
metastatic disease than cells cultured in either cytokine alone. 
Importantly, cells cultured without a cytokine during sec- 
ondary in vitro sensitization did not eradicate metastatic dis- 
ease even at the highest dose (3  x  106) of cells delivered. 
In one of two experiments, a small but significant decrease 
below HBSS treatment controls was seen with 3  x  106 and 
106 cells derived from cultures with no cytokine, but this 
was significantly  less than the therapeutic effect obtained with 
I1:7 or II:2 antitumor CTL at the equivalent cell dose. Fresh 
DLN, directly harvested from mice 7 d after footpad inocu- 
lation with the syngeneic autologous MCA 203 tumor, also 
had no therapeutic effect in three of three experiments. This 
latter finding established  the necessity of secondary in vitro 
sensitization for the generation of therapeutic effector cells. 
Supportive cytokine treatment with I-L-2  in adoptive therapy 
with secondarily stimulated antitumor CTL has been shown 
to augment the efficacy of cells in vivo,  generally twofold 
(16). In adoptive immunotherapy with TIL, a three- to fivefold 
augmentation in efficacy has been reported (19). The effect 
of supportive I1:2 on I1:7 antitumor CTL was evaluated by 
comparing the effect of delivering I1:2  (60,000  U/dose) or 
HBSS intraperitoneally twice daily for 5 d after titrated cel- 
lular adoptive transfer with CTL generated from DLN. As 
shown in Table 2, I1:2 augmented the efficacy of 11:7 and 
Table  1.  Comparison of lL-7, IL-2, and IL-7 Plus IL-2 Versus No Cytokine  in Generation of Antitumor CTL 
Mean no. of pulmonary 
metastases (SEM)* 
Culture  No. of cells 
Group  condition*  transferredS  IL-21I  Exp.  1  Exp. 2  Exp. 3 
A  -  HBSS  -  232 (18)  248 (2)  250 (0) 
B  -  HBSS  +  213  (36)  242  (4)  250 (0) 
C  IL-7  3  x  106  +  0 (0)  0 (0)  0 (0) 
D  IL-7  106  +  3 (2)  27 (20)  ND 
E  IL-7  5  x  10  s  +  89 (14)  108 (24)  ND 
F  IL-2  3  x  106  +  1 (1)  0 (0)  ND 
G  IL-2  106  +  33 (6)  52 (28)  ND 
H  IL-2  5  x  105  +  214 (34)  96 (36)  ND 
I  IL-7  +  IL-2  3  ￿  10 6  +  0  (0)  0  (0)  ND 
J  IL-7  +  IL-2  106  +  134 (18)  35 (13)  ND 
K  IL-7  +  IL-2  5  x  10  s  +  234 (16)  97 (36)  ND 
L  No cytokine  3  x  106  +  238  (12)  187 (32)  ND 
M  No cytokine  106  +  242  (8)  176 (34)  ND 
N  No cytokine  5  x  105  +  250 (0)  250 (0)  ND 
O  Fresh DLN  I  3  x  10  6  +  208 (32)  174 (38)  250 (0) 
* Statistical significance of differences:  Exp.  1,  A  vs.  C,  D,  E,  F,  G,  I,  or J, i82 <  0.05;  A  vs.  B,  H,  K,  L,  M,  N,  or O,  not  significant; C  vs. 
E,  G,  H, J,  K,  L,  M,  N,  or O, 1o2 <  0.05;  C  vs.  D,  F,  or I,  not  significant;  E  vs.  F,  G,  l,  K,  L,  M,  N,  or O, p2 <  0.05;  E  vs.  H  or J,  not 
significant.  Exp.  2, A  vs.  C,  D,  E,  F,  G,  H,  I, J,  K,  L,  or O, p2 <  0.05;  A  vs.  B,  M,  or N,  not  significant; C  vs. D,  E,  G,  H, J,  K,  L,  M, 
N,  or O, p2 <  0.05;  C  vs.  F  or  I,  not  significant; E  vs.  F,  I, J,  or N, 102 <  0.05;  E  vs.  G,  H,  K,  L,  M,  or O,  not  significant.  Exp.  3,  A  vs. 
B  or O,  not  significant;  C  vs.  A,  B,  or O, p2 <  0.05. 
* B6 mice popliteal DLN were harvested 7 d  after footpad inoculation with MCA 203. DLN cells were restimulated in vitro and cultured for 11 d 
before adoptive transfer. 
S B6 mice were inoculated intravenously with 5  x  10  s 203 MCA  tumor.  3  d  later,  antitumor CTL  were given intravenously in 1 ml of HBSS. 
II IL-2,  10,000  U/dose,  was  delivered twice daily for 5  d  intraperitoneaUy. 
I B6 mice popliteal DLN cells were harvested 7 d after footpad inoculation with MCA 203 and adoptively transferred without further in vitro culture. 
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I1,7 antitumor CTL delivered without cytokine support were 
as effective as those CTL generated with IL-2 in eradicating 
metastases. Overall, five comparisons of II,7 vs. II:2 antitumor 
CTL without supportive cytokine treatment  showed them 
to be equivalent in antitumor CTL efticacy, and in one case, 
the I1,7 antitumor  CTL were significantly better. 
IL-7 was also tested as a supportive cytokine. The I1,7 dose 
used (20 #g/dose) matched the I1,2 dose of 60,000 U on the 
basis of the weight of the protein content  of cytokine ad- 
ministered.  IL-7 as a supportive cytokine for I1,2 antitumor 
CTL resulted in significantly  less metastatic disease than HBSS 
control-treated  groups in two of three experiments.  In no 
case  did  I1,7  support  of  I1,7  antitumor  CTL  result  in 
significantly better antitumor effects than was seen with HBSS 
administration  (data not  shown). 
To determine the in vivo specificity of I1,7 antitumor CTL, 
cells generated against MCA 203 and 205 tumors were adop- 
tively transferred in a 3-d pulmonary metastatic model with 
10,000 U II.-2 administered intraperitoneally twice daily for 
five consecutive days. As shown in Table 3, adoptively trans- 
ferred cells effectively treated only the respective autologous 
tumor when tested in the crossover pattern.  These results 
demonstrated  the  specificity of MCA  203  and  205  I1,7- 
generated antitumor  CTL in vivo. 
In this report, we studied the in vivo efhcacy of antitumor 
CTL generated with 11,7. Our findings now extend the ma- 
ture T cell-activating effects of IL-7 (12-14; andJicha, D. L., 
S. Schwarz, J. J. Mul6, and S. A. Rosenberg, manuscript sub- 
mitted for publication) to include the induction of antitumor 
effector cells with therapeutic efficacy in vivo. We demon- 
strate  that  I1,7-generated  antitumor  CTL  are  effective in 
treating  3-d pulmonary metastatic disease from syngeneic, 
autologous tumor. Further, cells generated in Ib7 are as po- 
Table  2.  IL-2 as a Supportive Cytokine  with IL-7 and IL-2 Antitumor CTL 
Mean no.  of pulmonary 
metastases (SEM)* 
Culture  Cytokine 
Group  condition*  No.  of cellsS  suppord  Exp.  1  Exp.  2  Exp.  3 
A  -  HBSS  HBSS  250'1(0)  250 (0)  250 (0) 
B  -  HBSS  IL-2  250 (0)  250 (0)  250 (0) 
C  IL-7  3  x  10'  HBSS  0 (0)  0 (0)  0 (0) 
D  IL-7  106  HBSS  16 (6)  30 (22)  3 (3) 
E  IL-7  5  x  10.  HBSS  221 (20)  138 (38)  66 (38) 
F  IL-2  3  x  10.  HBSS  1 (1)  0 (0)  0 (0) 
G  IL-2  106  HBSS  249 (1)  59 (26)  27 (26) 
H  IL-2  5  x  10  s  HBSS  250 (0)  204 (29)  143 (43) 
I  It-7  3  x  10'  IL-2  0  (0)  0  (0)  1  (1) 
J  IL-7  106  IL-2  1 (1)  3 (3)  2 (1) 
K  IL-7  5  x  105  IL-2  91 (35)  53 (20)  8 (5) 
L  IL-2  3  x  106  IL-2  0 (0)  1 (1)  0 (0) 
M  IL-2  106  IL-2  44 (15)  56 (28)  3 (2) 
Y  IL-2  5  x  10.  IL-2  226 (13)  154 (39)  94 (34) 
* Statistical significance of differences:  Exp.  1,  B  vs.  C,  D,  F,  I, J,  K,  L,  M,  or N, p2 <  0.05;  B  vs.  A,  E,  G,  or H,  not  significant; C  vs.  D, 
E,  G,  H,  K,  M,  or N, p2 <  0.05;  C  vs.  F,  I, J,  or L,  not  significant; D  vs. E,  F,  G,  H,  I, J,  K,  L,  or N, p2 <  0.05;  D  vs. M,  not significant; 
E  vs.  F,  I, J,  K,  L,  or M,/'2 <  0.05;  E  vs.  G,  H,  or N,  not significant; I  vs.  K,  M,  or N,/'2 <  0.05;  I  vs. J  or L,  not significant; J  vs.  K,  M, 
or N,/'2 <  0.05; J  vs. L,  not significant; K  vs. L  or N, p2 <  0.05;  K  vs. M,  not significant. Exp.  2,  A  vs. C,  D,  E,  F,  G,  I, J,  K,  L, M,  or N, 
p2 <  0.05;  A  vs.  B  or H,  not  significant;  C  vs.  E,  G,  H,  K,  M,  or N,/'2 <  0.05;  C  vs.  D,  F,  I, J,  or L,  not  significant; D  vs.  E  or H,/'2 < 
0.05;  D  vs.  F,  G,  I, J,  K,  L,  M,  or N,  not significant; E  vs.  F,  I, J,  or L, p2 <  0.05;  E  vs. G,  H,  K,  M,  or N,  not  significant; I  vs.  K,  M,  or 
N, p2 <  0.05;  I vs. J  or L, not significant; J  vs. K,  M, or N, p2 <  0.05; J  vs. L, not significant; K  vs. L,/'2 <  0.05;  K  vs. M  or N,  not significant. 
Exp.  3,  A  vs.  C,  D,  E,  F,  G,  H,  I, J,  K,  L,  M,  or N,/'2 <  0.05;  A  vs. B, not significant; C  vs.  E,  H,  or N,/'2 <  0.05;  C  vs.  D,  G,  I, J,  K, 
L,  or M,  not significant; D  vs.  E,  H,  or N, p2 <  0.05;  D  vs.  F,  G,  I, J,  K,  L,  or M,  not significant; E  vs.  F,  G,  I, J,  K,  L,  or M, p2 <  0.05; 
E  vs.  H  or N,  not significant; I  vs.  N, p2 <  0.05;  I  vs. J,  K,  L,  or M,  not significant; J  vs.  N, p2 (  0.05; J  vs.  K,  L,  or M,  not significant; K 
vs.  L, p2 <  0.05;  K  vs.  M  or N,  not significant. 
* B6 mice popliteal DLN were harvested 7 d  after footpad inoculation with MCA 203. DLN cells were restimulated in vitro and cultured for 11 d 
before adoptive transfer. 
S B6 mice were inoculated intravenously with 5  x  10  s 203 MCA  tumor.  3  d  later,  antitumor CTL were given intravenously in 1 ml of HBSS. 
tl IL-2,  60,000  U/dose,  or HBSS was  delivered twice daily for 5  d  intraperitoneally. 
￿82  n  =  4,  in all other groups  n  ~  5  or greater. 
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Mean no.  of pulmonary 
metastases (SEM)* 
In vitro  No.  of cells  MCA tumor 
Group  MCA tumor~  transferredS  IL-211  treated~  Exp.  1  Exp.  2 
A  -  HBSS  -  203  250  (0)  250 (0) 
B  -  HBSS  +  203  250 (0)  250 (0) 
C  203  3  x  1@  +  203  0  (0)  0  (0) 
D  205  3  x  106  +  203  250 (0)  250  (0) 
E  -  HBSS  -  205  228  (22)  250  (0) 
F  -  HBSS  +  205  250  (0)  250 (0) 
G  203  3  x  106  +  205  248  (2)  250  (0) 
H  205  3  x  106  +  205  0  (0)  0  (0) 
" Statistical significance of differences: Exp.  1 and 2, C vs. A, B, D, E, F, or G, p2 < 0.001; C vs. H, not significant; H vs. A, B, D, E, F, or 
G, p2 < 0.001. 
B6 mice popliteal DLN were harvested 7 d after footpad inoculation with MCA 203 or 205. DLN cells were restimulated with their respective 
irradiated tumors  in vitro,  as noted,  and cultured for 11 d in IL-7 before adoptive transfer. 
S B6 mice were treated intravenously with antitumor  CTL or HBSS 3 d after tumor was delivered to mice. 
II IL-2 (10,000 U/dose)  or HBSS was delivered intraperitoneally twice daily for 5 d. 
ql Mice were inoculated intravenously with 5  x  105 MCA 203 or 205 tumor as specified. 
tent  as  I1:2-generated  antitumor  CTL.  We confirmed  the 
necessity of II,7 or I1:2 in our antitumor CTL cultures for 
the generation of antitumor ceils at the cell titrations deliv- 
ered. Specificity of I1:7 antitumor CTL in vivo in a crossover 
experiment with the MCA 203 and 205 tumors is also shown. 
To our knowledge, these results represent the first successful 
therapeutic adoptive transfer of cells grown in a cytokine other 
than I1:2. This work further suggests that II:7 may have an 
important  role in  adoptive immunotherapy. 
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